DGAP-News: Novavax to Present RSV Vaccine Clinical and Preclinical Results at ICAAC
(firmenpresse) - Novavax, Inc.
03.09.2013 14:30
---------------------------------------------------------------------------
ROCKVILLE, Md., 2013-09-03 14:30 CEST (GLOBE NEWSWIRE) --
Novavax, Inc. (Nasdaq:NVAX) a clinical-stage biopharmaceutical company creating
novel vaccines based on recombinant nanoparticle technology, today announced
that it will present data from recent clinical and preclinical studies of its
respiratory syncytial virus F-protein (RSV F) nanoparticle vaccine candidate in
poster sessions at the 53rd Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC) in Denver Colorado, September 11-13, 2013.
One poster will describe in detail the immunogenicity and safety of Novavax'
RSV F nanoparticle vaccine observed in a Phase 1 clinical study of 220 healthy
elderly adults (>=60 years of age, mean age of 68 years of age), top-line
results of which were reported by Novavax in July. The second poster will
present data from a preclinical passive immunization and challenge study which
evaluated the protective effects of RSV F nanoparticle vaccine-induced
palivizumab-like antibodies in a relevant model, the cotton rat, which was
previously predictive for protection in infant passive immunization studies.
The poster presentation numbers, titles, dates and times are listed below:
-- Poster B-501d: 'RSV F Protein Vaccine Is Well-Tolerated and Immunogenic in
Elders' will present data from the company's recently completed Phase 1
clinical trial of its RSV vaccine candidate in healthy elderly adults.
[Exhibit Hall A, Wednesday, September 11 from 11:00am to 1:00 pm]
-- Poster B-501a: 'Passive Immunization with RSV F Vaccine-Induced Polyclonal
Antibodies Protect Cotton Rats From RSV A Challenge' [Exhibit Hall A,
Wednesday, September 11 from 11:00am to 1:00 pm]
About RSV
RSV is a major respiratory pathogen in all humans regardless of age. In
healthy adults, RSV infections are generally mild to moderate in severity, but
may be more severe in infants and young children as well as the elderly and
adults with underlying chronic cardiac or pulmonary disease. It is estimated
that between 11,000 to 17,000 adults die of RSV infection annually in the U.S.,
with up to 180,000 hospitalizations for serious respiratory symptoms. Globally,
RSV is a common cause of childhood respiratory infection, with a disease burden
of 64 million cases and approximately 160,000 deaths annually. Severe RSV
disease results in 3.4 million hospital admissions per year globally and
disproportionately affects infants below six months of age. Currently, there is
no approved RSV prophylactic vaccine available.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines to address a broad range of infectious diseases
worldwide. Using Innovative proprietary recombinant protein nanoparticle
vaccine technology, as well as new and efficient manufacturing approaches, the
company produces vaccine candidates to efficiently and effectively respond to
both known and newly emergent diseases. Novavax is involved in several
international partnerships, including collaborations with Cadila
Pharmaceuticals of India, LG Life Sciences of Korea, PATH and recently acquired
Isconova AB, a leading vaccine adjuvant company located in Sweden. Together,
Novavax' network supports its global commercialization strategy to create real
and lasting change in the biopharmaceutical and vaccinology fields. Additional
information about Novavax is available on the company's website, novavax.com.
Forward-Looking Statements
Statements herein relating to the future of Novavax and its ongoing development
of its recombinant nanoparticle vaccine products are forward-looking
statements. Novavax cautions that these forward-looking statements are subject
to numerous risks and uncertainties, which could cause actual results to differ
materially from those expressed or implied by such statements. These risks and
uncertainties include those identified under the heading 'Risk Factors' in the
Novavax Annual Report on Form 10-K for the year ended December 31, 2012, and
Form 10-Q for the period ended June 30, 2013, both filed with the Securities
and Exchange Commission (SEC). Investors are cautioned not to place
considerable reliance on forward-looking statements contained in this press
release and encouraged to read the Company's filings with the SEC, available at
www.sec.gov, for a discussion of these and other risks and uncertainties. The
forward-looking statements in this press release speak only as of the date of
this document, and Novavax undertakes no obligation to update or revise any of
the statements. Novavax' business is subject to substantial risks and
uncertainties, including those referenced above and investors, potential
investors, and others should give careful consideration to these risks and
uncertainties.
CONTACT: Barclay Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
News Source: NASDAQ OMX
03.09.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Novavax, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US6700021040
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.09.2013 - 14:30 Uhr
Sprache: Deutsch
News-ID 292890
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Novavax to Present RSV Vaccine Clinical and Preclinical Results at ICAAC"
steht unter der journalistisch-redaktionellen Verantwortung von
Novavax, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
